Latest Jazz Pharmaceuticals plc Stories
Posters Include an Epidemiological Measure of the Effectiveness Analysis of Defibrotide from a Phase 3 Trial in Severe Hepatic VOD, as well as Updates from an International Compassionate Use Program
Company Reports Third Quarter 2014 Total Revenues of $307 Million, Driven by Strong Sales of Xyrem, Erwinaze and Defitelio DUBLIN, Nov.
Company Reports Second Quarter 2014 Total Revenues of $291 Million, Driven by Strong Sales of Xyrem, Erwinaze and Defitelio DUBLIN, Aug.
Jazz Pharmaceuticals owns worldwide rights to defibrotide DUBLIN, Aug.
DUBLIN, July 22, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2014 second quarter financial results on Tuesday, August 5, 2014,
- an ornament or knob in the shape of a flower